{"id":"W4404354036","doi":"10.1016/s1470-2045(24)00507-2","title":"Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario","funders":"National Cancer Institute; NRG Oncology; National Center for Advancing Translational Sciences; AstraZeneca; U.S. Department of Veterans Affairs","keywords":"Cetuximab; Durvalumab; Medicine; Contraindication; Head and neck cancer; Cisplatin; Oncology; Radiation therapy; Internal medicine; Randomized controlled trial; Head and neck; Cancer; Surgery; Chemotherapy; Alternative medicine; Colorectal cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002677594,0.001270059,0.002175851,0.0003279337,0.0003313371,0.0005959938,0.00105598,0.001320822,0.004339056],"category_scores_gemma":[0.001879556,0.0005751835,0.001402912,0.0003429505,0.00102119,0.0007846619,0.0004559283,0.002020908,0.0006209674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009820075,"about_ca_system_score_gemma":0.001511208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008245957,"about_ca_topic_score_gemma":0.002897295,"domain_scores_codex":[0.999076,0.0006210681,0.0000449603,0.0001145662,0.00005185213,0.0000915074],"domain_scores_gemma":[0.9991738,0.0002277632,0.0001985211,0.00007519119,0.00004685114,0.0002778674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9732085,0.008244262,0.0007341256,0.0003726858,0.0004389921,0.00003483075,0.00005054334,0.0005350166,0.00285454,0.00009305638,0.0005364881,0.01289688],"study_design_scores_gemma":[0.9288034,0.06904136,0.0009050221,0.00001360374,0.0002097078,0.00001958896,0.000008807106,0.0002670723,0.0002695176,0.00009541338,0.0003591033,0.00000732249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905207,0.001473951,0.0005443584,0.0004197505,0.0003212686,0.005043524,0.0004603345,0.00006898501,0.001147043],"genre_scores_gemma":[0.9868297,0.001216312,0.002141331,0.0007532076,0.0002572965,0.006144474,0.0005915632,0.00001641934,0.002049709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004339056,"threshold_uncertainty_score":0.01451564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06597821994464595,"score_gpt":0.4267055373765256,"score_spread":0.3607273174318796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}